Aprea Therapeutics Announces Acquisition Of Atrin Pharmaceuticals Inc. And Reports First Quarter 2022 Financial Results
Acquiring Company
Aprea Therapeutics
Acquired Company
Eton Pharmaceuticals
DoylestownDeer ParkBiotechnologyHealth CareScience And EngineeringTherapeuticsBiotechnologyHealthcareHealth CarePharmaceuticalDescription
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022.
Quick answer
Aprea Therapeutics is acquiring Eton Pharmaceuticals, announced May 16, 2022. Aprea Therapeutics is based in Doylestown, Pennsylvania, United States.
- How much did Aprea Therapeutics pay for Eton Pharmaceuticals?
- The deal value was not disclosed.
- What does Aprea Therapeutics do?
- Aprea Therapeutics (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality.
- Where are Aprea Therapeutics and Eton Pharmaceuticals based?
- Aprea Therapeutics is based in Doylestown, Pennsylvania, United States. Eton Pharmaceuticals is based in Deer Park, Illinois, United States.
- Who are the decision-makers at Aprea Therapeutics?
- Fundz holds 1 contact at Aprea Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Science And Engineering and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Regeneron Completes Acquisition Of Checkmate Pharmaceuticals (May 31, 2022)
- Regeneron To Acquire Checkmate Pharmaceuticals And Its Investigational Immune Activator For Potential Use In Multiple Tumor Types (April 19, 2022)
- Pfizer To Acquire Biohaven Pharmaceuticals (May 10, 2022)
- Bristol Myers Squibb To Acquire Turning Point Therapeutics, A Leading Precision Oncology Company (June 3, 2022)
- Halozyme Completes Antares Pharma Acquisition (May 24, 2022)
- Hikma Completes Acquisition Of Custopharm (April 21, 2022)
Who to call at Aprea Therapeutics, and when
When Aprea Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Aprea Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aprea Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aprea Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aprea Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Eton Pharmaceuticals?
Eton Pharmaceuticals was acquired by Aprea Therapeutics, based in Doylestown. The deal was reported on May 16, 2022. Aprea Therapeutics (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Aprea Therapeutics is publicly traded (APRE) and operates in Biotechnology.
When did Aprea Therapeutics acquire Eton Pharmaceuticals?
Aprea Therapeutics's acquisition of Eton Pharmaceuticals was reported on May 16, 2022. Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Eton Pharmaceuticals do?
Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. It is publicly traded (ETON), operating in Biotechnology, and is based in Deer Park.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.